Form 4: Southpoint Capital Sells Fennec Pharma Shares

Southpoint Capital Advisors, a 10% owner and director, reported the sale of 19,341 Fennec Pharmaceuticals common shares at a weighted average price of $8.7921 per share.

Summary

• Southpoint Capital Advisors LP and related entities, including John S. Clark II, reported the sale of Fennec Pharmaceuticals Inc. common stock.
• A total of 19,341 shares were disposed of on November 18, 2025.
• The shares were sold at a weighted average price of $8.7921 per share, with individual trades ranging from $8.75 to $8.845.
• Following this transaction, the reporting persons beneficially own 3,744,741 shares indirectly through Southpoint Master Fund, LP.
• The transaction was executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 4

Explanation: The sale of shares by a 10% owner and director, even under a pre-arranged plan, generally carries a slightly negative sentiment as it reduces insider alignment, though the impact is mitigated by the 10b5-1 plan and the remaining substantial holding.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than an immediate reaction to new, undisclosed information.

Negatives

• A 10% owner and director reduced their stake in the company.
• The sale represents a reduction in the reporting person's direct or indirect exposure to Fennec Pharmaceuticals.

Risks

• Potential negative market perception due to a significant shareholder and director reducing their holdings.
• Future sales by large shareholders could exert downward pressure on the stock price.

Future Outlook

The filing does not provide specific forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on the reported insider transaction.

Management Comments

• The filing includes a disclaimer from the reporting persons stating they disclaim beneficial ownership of the shares reported except to the extent of their pecuniary interest therein.

Industry Context

Insider sales, particularly by significant shareholders and directors, are closely watched by the market as they can sometimes signal a lack of confidence or a rebalancing of portfolios. In the pharmaceutical industry, such sales are often evaluated against company-specific milestones, clinical trial results, or regulatory approvals, though this filing does not provide such context.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: May interpret the sale as a signal from a significant insider, potentially influencing their investment decisions.

Next Steps

• The filing does not specify any future actions, events, or milestones for Fennec Pharmaceuticals or the reporting persons beyond the reported transaction.

Key Dates

Recommendation

While a director and 10% owner sold shares, the transaction was executed under a Rule 10b5-1 plan, suggesting a pre-scheduled portfolio rebalancing rather than a reaction to new negative information. The reporting persons still retain a substantial holding of over 3.7 million shares. This transaction alone does not provide sufficient new information to warrant a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate pending further company-specific news or broader market developments.

Keywords

Fennec Pharmaceuticals, FENC, Southpoint Capital Advisors, Insider Sale, Form 4, Beneficial Ownership, Equity Sale, 10b5-1 Plan